Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in⦠read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
$0.73
Price+10.69%
$0.07
$60.359m
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$0.00
-
1y CAGR-
3y CAGR-
5y CAGR-$117.320m
-
1y CAGR-
3y CAGR-
5y CAGR-$1.30
-
1y CAGR-
3y CAGR-
5y CAGR$161.446m
$191.271m
Assets$29.825m
Liabilities$16.245m
Debt8.5%
-0.1x
Debt to EBITDA-$97.297m
-
1y CAGR-
3y CAGR-
5y CAGR